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threshold for cost-effectiveness. The objective of this research was to investigate 
the methodology used in public health modelling, to determine the effect that 
this has on predicted cost-effectiveness and to make recommendations about the 
most appropriate methods to use. Methods: We reviewed past NICE public health 
guidance and the associated economic evaluations to assess if methods tended 
to be based on the ICER alone or if other benefits are taken into account. In those 
instances where non-health benefits are included, we evaluated how this was done 
and if it was done consistently. Results: Results showed that a range of method-
ologies were used to evaluate public health interventions in the UK and that the 
methods used were inconsistent. ICERs were often calculated despite not always 
being the most appropriate measure. There tended to be considerable uncertainty 
around data inputs in the majority of economic evaluations. ConClusions: The 
methods used to evaluate public health interventions in the UK vary, mostly by the 
type of economic evaluation and the perspective taken. ICERs were not always the 
most appropriate outcome. Variations in the methods could result in inconsistent 
recommendations across Public Health Guidance.
PRM41
Budget IMPact analysIs In the uk settIng – know youR audIence
Guy H, Lee A, Murphy D
WG Access Ltd, London, UK
objeCtives: When developing a budget impact model (BIM) the design stage is 
key. A particular element which should be carefully considered during the design 
phase is the perspective and in particular who the audience will be. The objec-
tive of this study was to identify who the potential users and healthcare decision-
makers may be and what elements should be captured within the BIM to meet their 
requirements within a UK setting. Methods: Research was conducted in a staged 
approach. The first stage involved identifying the different types of potential users 
of a BIM. Following identification of these different users, the next stage of research 
sought to identify the cost criteria each user is expected to assess a BIM against, thus 
informing what should be captured in an analysis. The final stage then identified 
what cost categories are required in a BIM to satisfy these criteria. Results: Two 
main users of a BIM were identified: providers and commissioners. The criteria that 
a provider is expected to consider is: what is the incremental cost and resource use 
implications of providing the intervention in question? What is the incremental 
income that will be received for providing this intervention? Whereas, the criteria 
that a commissioner is expected to consider are: what is the incremental cost of 
commissioning the provision of the intervention? Is there any added value in terms 
of quality, capacity or outcomes? An example of appropriate costs which are aligned 
with the perspective of a provider and commissioner, would be NHS reference costs 
and national tariffs, respectively. ConClusions: Determining the audience of a 
BIM is crucial in designing a model fit for purpose. Key requirements of a BIM will 
be dependent on the audience, in particular capturing costs appropriately. Research 
should be conducted for other countries.
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objeCtives: Now in Ukraine state, regional and private budgets on country, 
regional, institutional and personal levels have substantial level of insufficiency. 
Human productivity is the main national asset for economic recovery, so, health 
care system could make significant impact and guarantee sustain economic 
growth. Therefore, every decision within Ukrainian healthcare system must be jus-
tified clinically and economically. With the purpose to prepare basis for economic 
justification the analysis of health-related cost categories specific for Ukraine was 
performed. Methods: Direct cost are specific for Ukrainian Healthcare system 
were drawn in 3 main categories: outpatient, inpatient and emergency (pre-hospi-
talization) costs. Macroeconomic result categories, Tax and Work policy, tariffs for 
services in healthcare system and standards for care were analyzed to determine 
cost units and cost compositions. Four payer perspectives were considered: state 
budget and funds; patient and family; employer; insurance company. Results: 
In result, health-related costs are specific for Ukraine and approaches for calcu-
lation were determined. Outpatient costs: outpatient visit costs (physician and 
nurse salary); diagnostic measures costs (laboratory or instrumental required by 
healthcare standards); treatment costs (basis or course required by healthcare 
standards). Inpatient costs: hospital-days costs (daily accommodation & care); 
diagnostic measures costs (laboratory or instrumental required by healthcare 
standards); treatment costs (single intake or course required by healthcare 
standards). Emergency costs: visit costs (physician and nurse salary); diagnostic 
measures costs (laboratory or instrumental required by healthcare standards); 
treatment costs (single intake required by healthcare standards); transportation 
costs (driver salary, fuel and amortization costs). ConClusions: Costs are drawn 
in current study to be validated internally in Ukraine with the State-Healthcare, 
Legislation, Economic experts. An external validation to be performed as well by 
the comparison of costs and cost categories with the same in other countries. 
After the validation, current cost matrix is planned to be integrated in population 
model for Cost of Illness Analysis.
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a similar number of cycles in the non-cirrhotic for both the simple and complex 
model. This was done by calculating: (1) the expected number of cycles in F0F3 
before transitioning to F4 (E) in the simple model; (2) the minimum number of cycles 
from Fn to F4 adjusted for the fibrosis stage distribution; (3) the (I-T)^-1 matrix equal 
to the average number of cycles in each Fn state based on (1) and (2); (4) the T matrix 
corresponding to the transition probability for Fn to Fn+1. Results: Based on a 
F0F3 to F4 TP of 0.04 and a fibrosis stage distribution of 23% F0 & F1, 27% F2 & F2, we 
obtained Fn to Fn+1 TP = 0.097. For both the simple and complex models E was equal 
to 25. However, the sum of cycles in the non-cirrhotic states after only 50 cycles 
were 20.12 and 21.92 for the simple and complex models respectively. Taking into 
account a 2% discounting the sums were 13.83 and 8.59. ConClusions: Markov 
models are sensitive to their structure, even when properly fitting the TP. For HCV, 
changing from a simple to a complex model is not trivial.
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objeCtives: The goal of our poster is to analyse the costs of treatment of the 
new antiviral therapies against the Hepatitis C virus (HCV) submitted to the 
Department of Health Technology Assessment of the National Institute of 
Pharmacy and Nutrition. Methods: In our analysis, we examined the cost of 
treatment with the available interferon (IFN)-based and IFN-free therapies based 
on the current PUPHA database from the official website of National Health 
Insurance Fund of Hungary. The cost estimates have been made in two different 
ways both from the payer’s view. The first calculation does not take into account 
the success of therapy as it’s based on the SPC with the assumption of a com-
plete possible length of the treatment. The second calculation method is based 
on the sustained virologic response (SVR) which has become the best indication 
of therapeutic success. Results: Performance-based risk-sharing arrangements 
should be based on an endpoint which is meaningful both from the payer’s and 
the patients’ perspective, which can be measured objectively and which depends 
primarily on the applied therapy. This endpoint is the SVR rate in the treatment of 
HCV. The SVR rates were between 34,4% and 95% in the relevant clinical studies. 
The cost of the therapy ranges between 8.4 million HUF and 31 million HUF, if we 
do not take into account the SVR rates. ConClusions: Following a more than 
two decades of intense research, the interferon-free era of hepatitis C treatment 
has arrived. The availability of IFN-free regimens allows many patients who could 
not be treated previously because of medical or psychiatric contraindications or 
an inability to tolerate IFN to receive treatment. Introduction of these new HCV 
drugs put a financial strain on the payer. The use of performance-based financing 
is a way to maintain the balance of the budget.
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objeCtives: Methodological research focused on resource use measurement has 
been limited in comparison to the amount of research focussed on measuring out-
comes within the economic evaluation context. This study was designed to assess 
the level-of-agreement between two different sources of health and social care 
resource use data collected on care home residents. Methods: The methods were 
informed by a review of level-of-agreement studies concerned with resource use 
in older people. In the base case, resource use data collected from both GP medical 
records (electronic records) and care home records (paper-based records) on 362 
care home residents were obtained as part of the CAREMED cluster randomised 
controlled trial. Descriptive statistics were explored before assessing level-of-agree-
ment through percent agreement, 95% limits of agreement, and Lin’s concordance 
correlation coefficient (CCC). Sensitivity analyses excluded non-users and tested 
timeframe. Factors affecting the magnitude of difference were explored using multi-
level modelling. Results: Several resource items (number of GP, out of hours GP 
and podiatrist contacts) were found to have substantial agreement (0.61 to 0.80) 
between the GP records and care home records according to the CCC. The number of 
total visits, dietician, paramedic and SLT contacts showed moderate agreement (0.41 
to 0.60). Most resources showed a poor (less than 0.00) or slight (0.00 to 0.22) level-
of-agreement either due to care home records (for chiropodist, music therapy, and 
social worker contacts) or GP records (for phlebotomist and practice nurse) record-
ing a greater number of visits. Patient classification (residential/nursing), number 
of falls, number of STOPP criteria met, number of medications and comorbidities 
significantly affected the magnitude of differences observed. ConClusions: This 
research suggests that both sources of data are reliable for some resources but 
not others, indicating dual sources may be necessary where a wider perspective is 
important and feasible in terms of costs of data collection.
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objeCtives: Quality-adjusted life years (QALYs) are commonly used in health tech-
nology appraisals, including those by NICE in the UK. However, QALYs only include 
‘health-related’ quality of life (QOL) which may not apply to interventions that 
have benefits and costs that fall outside of the NHS. NICE recommends that public 
health economic evaluations take a cost consequence or cost benefit approach 
and present a public sector or societal perspective. However, it is not clear how or 
if the costs and benefits that fall outside the NHS should be incorporated into this 
